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Objective Evaluate clinical effectiveness of the first trimester
combined (FMF) pre-eclampsia screening programme when
implemented in a public healthcare setting.
Design Retrospective cohort study.
Setting London tertiary hospital from January 2017 to March
2019.
Methods 7720 women screened for pre-eclampsia according to
National Institute for Health and Care Excellence (NICE) risk-
based guidance and 4841 by the Fetal Medical Foundation (FMF)
algorithm which combined maternal risk factors, blood pressure,
PAPP-A and uterine artery Doppler indices in the first trimester.
High risk was defined by standard NICE criteria in the pre-
intervention cohort (prescribed 75 mg aspirin) or a risk of ≥1:50
for preterm pre-eclampsia from the FMF algorithm in the post-
intervention cohort (prescribed 150 mg aspirin).
Main outcome measures Screening effectiveness, rates of pre-
eclampsia.
Results The FMF screening programme resulted in a significant
reduction in the screen-positive rate (16.1 versus 8.2%, odds ratio
[OR] 0.50, 95% confidence interval [CI] 0.41–0.53) with a
concurrent increase in targeted aspirin use in women classified as
high risk for pre-eclampsia (28.9 versus 99.0%, OR 241.6, 95% CI
89.6–652.0). Screening indices were uniformly improved for the
FMF algorithm with receiver operating characteristic (ROC)
analysis demonstrating excellent discrimination for preterm pre-
eclampsia (area under the curve [AUC] = 0.846, 95% CI 0.778–
0.915, P value <.001). Interrupted time series analysis showed that
the FMF screening programme resulted in a significant 21-month
relative effect reduction of 80% (P = .025) and 89% (P = .017),
for preterm and early pre-eclampsia, respectively.
Conclusions First trimester combined screening for pre-eclampsia
is both feasible and effective in a public healthcare setting. Such
an approach results in a two-fold de-escalation of risk, doubling
of pre-eclampsia detection, near total physician compliance of
aspirin use and a significant reduction in the prevalence of
preterm pre-eclampsia.
Keywords Aspirin, blood pressure, Doppler, first trimester,
PAPP-A, pre-eclampsia, screening.
Tweetable abstract Implementation of 1st trimester combined
pre-eclampsia screening effectively reduces prevalence of the
disorder.
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Introduction
Current screening recommendations for pre-eclampsia uti-
lise a medical, social and obstetric history-based approach
for the majority of international institutions such as the
American College of Obstetrics and Gynecology (ACOG),1
International Society for the Study of Hypertension in
Pregnancy (ISSHP)2 and National Institute for Health and
Care Excellence (NICE).3 For example, NICE recommends
that women are considered screen-positive for developing
pre-eclampsia if one major risk factor or any two moderate
factors are present. These recommendations for routine
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population screening for pre-eclampsia are made on the
basis of medical legacy rather than from an evidence base
of prospective studies, despite such an approach being gen-
erally considered to be clinically ineffective.4 Although the
majority of the risk factors used are statistically associated
with an increased risk of developing pre-eclampsia,5 criti-
cisms of the latter approach include low likelihood ratios
of the individual risk factors, lack of consideration for the
interactions between risk factors that might further weaken
likelihood ratios, and the inability to de-escalate pre-
eclampsia risk when protective factors are apparent, such as
previous normotensive pregnancy or average weight. As a
consequence of these limitations, the use of risk factor-
based approach results in high screen-positive rates and a
numerically indeterminate level of risk of pre-eclampsia in
the screen-positive group.
A recent National Institute of Health Research (NIHR)
funded study undertook a multi-centre head-to-head compar-
ison of NICE risk-based versus first trimester Fetal Medicine
Foundation (FMF) algorithm-based screening programmes for
pre-eclampsia.4 The authors demonstrated that multifactorial
algorithm-based screening using maternal history, blood pres-
sure, uterine Doppler and maternal serum biochemistry was
superior, with both a significant reduction in screen-positive
rate and an increase in detection for pre-eclampsia. The same
FMF algorithm-based screening tool was used to guide first tri-
mester low-dose aspirin prophylaxis and was subsequently
assessed in the Aspirin for Evidence-Based Pre-eclampsia
Prevention (ASPRE) randomised controlled trial.6 This ran-
domised controlled trial (RCT) established the efficacy of such
a screening programme in a research setting by demonstrating
a 62% (95% CI 26–80%) reduction in the incidence of pre-
term pre-eclampsia. The aim of this study is to evaluate the
clinical effectiveness of the FMF algorithm-based screening
programme when implemented in a routine NHS healthcare
setting by assessing prediction of pre-eclampsia, rates of pre-
eclampsia and maternal/fetal outcomes.
Methods
Following the publication of the ASPRE RCT results in August
2017, St George’s University Hospitals NHS Foundation Trust
implemented the first trimester FMF multifactorial algorithm-
based screening programme for pre-eclampsia in March 2018,
having previously routinely used NICE risk factor-based assess-
ment.3 In keeping with the intervention in the ASPRE study,
the use of aspirin prophylaxis in the high risk for pre-eclampsia
group was also changed from 75 to 150 mg once daily at that
time. Implementation was undertaken without any additional
financial support. The change of practice process included a
formal application for NICE exemption and multi-professional
education of midwives, sonographers, obstetricians, phar-
macists and general practitioners. Sonographers who
routinely undertook second trimester uterine artery Doppler in
high-risk pregnancy were trained to do this in the first trimester.
Time to undertake this assessment was enabled by the reduced
screen-positive rate and reduced numbers of follow-up scans
required with the new screening protocol. All singleton preg-
nancies booked at St George’s hospital prior to 14 weeks’ gesta-
tion were included. Exclusion criteria included multiple
pregnancy, fetal abnormalities, miscarriages, terminations and
those lost to follow up (see Figure S1 for participant flow infor-
mation).
RRisk for pre-eclampsia was defined as high in the NICE
screening cohort if one major risk factor (previous hyperten-
sive disorder of pregnancy, chronic hypertension, diabetes
mellitus, chronic kidney disease or autoimmune disease) or
any two moderate factors (nulliparity, maternal age
≥40 years, body mass index [BMI] at booking ≥35 kg/m2,
inter-pregnancy interval >10 years or family history of pre-
eclampsia) were present. Subsequent pregnancy management
was scheduled as dictated by NICE guidance. A risk cut-off
of ≥1:50 for preterm pre-eclampsia was considered high risk
using an FMF algorithm combining maternal factors, mean
arterial pressure (MAP), first trimester uterine artery pul-
satility index (UtA-PI) Doppler and pregnancy-associated
plasma protein A (PAPP-A). The risk cut-off of ≥1:100 for
preterm pre-eclampsia used in the ASPRE trial resulted in a
high screen-positive rate of 18% in our population, hence a
pragmatic decision was taken to reduce the cut-off to ≥1:50
with an expected screen-positive rate of approximately 10%.
Given the use of maternal serum PAPP-A (taken routinely
for trisomy screening) rather than placental growth factor
(PlGF) in the algorithm, we anticipated a detection rate of
76% for preterm pre-eclampsia at a 10% screen-positive
rate.4 If either PAPP-A or UtA-PI was not available, the FMF
algorithm was run with the other parameters on the basis
that the SPREE study4 demonstrated that even without one
of these measurements, first trimester FMF combined pre-
eclampsia screening remained more effective than conven-
tional NICE screening. All women with a risk of ≥1:50 for
preterm pre-eclampsia were offered serial scans (28 and
36 weeks) and induction of labour from 40 weeks’ gestation.
Outcome measures
Patients were not involved in the development of the
research, as the data for this study were derived from a retro-
spective analysis of routinely collected information from the
maternity birth registry and ultrasound databases between
January 2017 and March 2019. These databases are used rou-
tinely in healthcare service delivery and are subject to regular
clinical governance review. In addition, all hypertensive out-
comes and 500 non-hypertensive pregnancies were cross-
checked with individual maternity records to confirm
database accuracy and reliability. Details collected incl-
uded maternal demographic/pregnancy characteristics and
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previous medical history. Gestational age was determined by
crown–rump length (CRL) measurement performed at the
routine 11- to 13-week ultrasound scan.7 The MAP and
UtA-PI were assessed according to standardised protocols at
the same visit.8,9 Core outcome sets were not used. The pri-
mary outcomes were defined as the rates of pre-eclampsia at
various gestational ages at delivery, before and after intro-
duction of the FMF screening programme, and evaluation of
screening performance. Secondary outcomes included evalu-
ation of prescription of aspirin prophylaxis, rates of small-
for-gestational-age birth and severity of pre-eclampsia. Pre-
eclampsia was defined according to the criteria in the NICE
hypertension in pregnancy guidelines.3 Small for gestational
age was defined as a birthweight <10th centile, adjusted for
gestational age at birth. Fetal growth restriction was defined
as any of the following: abnormal fetal Doppler (umbilical
artery pulsatility index >95th centile and/or middle cerebral
artery pulsatility index <5th centile); or birthweight <10th
centile with abnormal fetal Doppler; or birthweight <3rd
centile; or intrauterine or neonatal death secondary to utero-
placental insufficiency. Severity of pre-eclampsia was defined
by the following criteria: two or more abnormal bloods and/
or polymerase chain reaction (PCR), according to the NICE
cut-off criteria for pre-eclampsia diagnosis3 (i.e. any mater-
nal biochemistry or haematology results outside the expected
reference range); use of magnesium sulphate for treatment of
severe pre-eclampsia; eclampsia or haemolysis, elevated liver
enzyme levels, and low platelet levels (HELLP) syndrome;
neonatal unit admission and hypertensive treatment needing
two or more agents. The latter was chosen, as rescue therapy
with a second (or more) antihypertensive medication to con-
trol hypertension is a good clinical proxy of severe hyperten-
sion and is more strongly associated with adverse pregnancy
outcome10 Maternal, fetal and neonatal outcomes of the
overall population are shown in Table S1.
Statistical analysis
Descriptive data were presented in median and interquartile
range for continuous variables and in numbers and percent-
ages for categorical variables. To detect whether the interven-
tion had a significantly greater effect than any temporal
confounding due to an underlying secular trend, an inter-
rupted time series (ITS) analysis using ARIMA modelling of
the primary outcomes of pre-eclampsia rates at various gesta-
tional age at delivery was performed11 and reported as the
relative effect change at 21 months post-intervention. In
short, data were organised as per the methods described in
Cochrane: Effective Practice and Organisation of Care.11 Esti-
mates for regression coefficients correlated with two standard-
ised effect sizes were calculated including a change in level
(also called ‘step change’) and a change in trend before and
after the intervention (Table S4).11 In the pre-inter-
vention period, the coefficient for ‘time’ gives the slope of the
regression line pre-intervention; the coefficient for ‘phase’ is
the point on the y-axis when projecting back the line for the
post-slope to the y-axis; and the coefficient for ‘interact’ is the
difference between the pre-slope and post-slope. Post interven-
tion, in each 3-monthly period, the coefficient for ‘phase’ is
the level effect at 3, 6, 12, 15, 18 and 21 months, respectively.
The model was then used to calculate the relative effect change
at each interval by the method described by Cochrane,11 which
included the ‘phase’ coefficient and predicted value. This was
reported at the 21-month post implementation interval to
interrogate the maximal effect of the new screening pro-
gramme. Comparisons between groups were performed using
the Mann–Whitney U-test for continuous variables and the v2
test or Fisher’s exact test for categorical variables. Odds ratios
Table 1. Maternal demographic and risk factor characteristics of
the study population managed with NICE or first trimester FMF
algorithm-based pre-eclampsia screening. Data shown as median
(interquartile range) or number (%)
Characteristic NICE screened
(n = 7720)
Combined
(FMF)
screened
(n = 4841)
P-
value
Weight (kg) 65.3 (58.0–75.0) 65.9 (58.6–75.4) 0.158
Height (cm) 163.5 (159–168) 164 (164–168) 0.287
Age (years) 33 (29–36) 32 (29–35) 0.223
MAP (mmHg) 86.7 (81.3–92.0) 86 (81.3–91.2) 0.344
Nulliparous 3890 (50.4%) 2484 (51.3%) 0.323
Ethnicity
White 5036 (65.5%) 3165 (65.4%) 0.882
Black 930 (12.0%) 547 (11.3%) 0.216
South Asian 1291 (16.7%) 814 (16.8%) 0.913
East Asian 269 (3.5%) 195 (4.0%) 0.128
Mixed 201 (2.6%) 120 (2.5%) 0.709
Smoker 321 (4.2%) 201 (4.2%) 0.216
Previous
pre-eclampsia
174 (2.3%) 122 (2.5%) 0.370
ART (IVF/ICSI/
other)
322 (4.2%) 179 (3.7%) 0.203
Renal disease 29 (0.4%) 29 (0.6%) 0.097
Autoimmune
disease
79 (1.0%) 69 (1.4%) 0.052
SLE/APLS 21 (0.3%) 17 (0.4%) 0.536
Pre-pregnancy
diabetes
54 (7.0%) 42 (8.7%) 0.343
Chronic
hypertension
94 (1.2%) 56 (1.2%) 0.825
APLS, antiphospholipid syndrome; ART, artificial reproductive
technology; BP, blood pressure; ICSI, intracytoplasmic sperm
injection; IVF, in vitro fertilisation; MAP, mean arterial pressure; SLE,
systemic lupus erythematosus.
Comparisons between outcome groups were by Chi-square or
Fisher exact test for categorical variables and Mann–Whitney U-test
for continuous variables.
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for each variable were calculated. Screening test evaluation
included sensitivity, specificity, positive and negative likelihood
ratios, positive and negative predictive values, and accuracy.
The statistical software packages SPSS 22.0 (SPSS Inc., Chi-
cago, IL, USA), GRAPHPAD (GraphPad Software, San Diego,
CA, USA) and MEDCALC (MedCalc Software, Mariakerke, Bel-
gium) were used for data analyses.
Results
Between January 2017 and March 2019, a total of 12 561
women attended the unit with singleton pregnancies prior
to 14 weeks’ gestation: 7720 underwent screening for pre-
eclampsia according to NICE guidance and 4841 using the
FMF screening algorithm. There were no significant differ-
ences in the maternal demographic characteristics or medi-
cal history between the two groups, with maternal age,
BMI, parity, ethnicity and pre-eclampsia risk factors being
comparable between both groups (Table 1).
Comparison of the NICE and FMF screening tests
There was a significant reduction in the screen-positive rate
(8.2 versus 16.1%, OR 0.50, 95% CI 0.41–0.53) with a
concurrent increase in targeted aspirin use in women classi-
fied as high risk for pre-eclampsia (99.0 versus 28.9%, OR
241.6, 95% CI 89.6–652.0) in the FMF compared with the
NICE screened cohorts (Table 2). The rate of aspirin pro-
phylaxis in women who developed pre-eclampsia was also
significantly higher in women screened using the FMF algo-
rithm (39.0 versus 24.5%, OR 1.97, 95% CI 1.27–3.06).
The detection rates for preterm pre-eclampsia after routine
aspirin prophylaxis using NICE and FMF screening algo-
rithms are also shown in Table 2—screening indices were
uniformly improved for FMF compared with NICE screen-
ing. The ROC analysis for FMF screening demonstrated
excellent discrimination for preterm pre-eclampsia (Fig-
ure S2: AUC = 0.846, 95% CI 0.778–0.915, SE 0.035,
P < 0.001). The screening characteristics for different risk
cut-offs to detect preterm and term pre-eclampsia are
shown in Tables S2 and S3.
Effect of the FMF screening programme on
pregnancy outcomes
With conventional odds ratio analysis, there was an apparent
23% reduction in the prevalence of pre-eclampsia in the
cohort managed with the FMF screening programme (2.8
Table 2. Comparison of screening performance, targeting use of aspirin prescription, pre-eclampsia rates and pregnancy outcomes in the NICE
and first trimester FMF algorithm-based pre-eclampsia screened cohorts. There were 65 (0.84%) and 27 (0.56%) preterm pre-eclampsia cases in
the NICE and FMF cohorts, respectively. Data presented as number (%) or screening test evaluation results
Outcome NICE screened
(n = 278)
Combined (FMF)
screened
(n = 136)
Odds ratio (95% CI) P-value 21 months’ relative
effect change
(ITS analysis)
P-value
Pre-eclampsia rates
Overall pre-eclampsia rate 278 (3.6) 136 (2.8) 0.774 (0.628–0.953) 0.016 44.3% 0.308
Pre-eclampsia at term
(≥37 weeks)
213 (2.7) 109 (2.3) 0.812 (0.643–1.026) 0.080 20.2% 0.739
Pre-eclampsia <37 weeks 65 (0.84) 27 (0.56) 0.661 (0.421–1.036) 0.071 80.0% 0.025
Pre-eclampsia <34 weeks 18 (0.23) 7 (0.14) 0.620 (0.259–1.485) 0.283 89.9% 0.017
Pre-eclampsia <30 weeks 8 (0.10) 0 (0) 0.094 (0.005–1.624) 0.104 – –
Screening and aspirin
Screen-positive (high-risk) 1242 (16.1) 397 (8.2) 0.496 (0.414–0.525) <0.001 – –
Screen-positive on aspirin 359 (28.9) 393 (99.0) 241.66 (89.56–652.04) <0.001 – –
Pre-eclampsia cases on aspirin 68 (24.5) 53 (39.0) 1.972 (1.270–3.062) 0.003 – –
Screening performance for preterm (<37 weeks) pre-eclampsia
Sensitivity 36.9% (25.3–49.8) 55.6% (35.3–74.5) 2.135 (0.859–5.311) 0.103 – –
Specificity 84.1% (83.6–84.9) 92.0% (91.2–92.8) 2.195 (1.945–2.478) <0.001 – –
Positive LR 2.3 (1.9–3.2) 7.0 (4.9–9.9) – – – –
Negative LR 0.75 (0.62–0.90) 0.48 (0.32–0.74) – – – –
Positive PV 1.9% (1.4–2.7) 3.8% (2.7–5.3) – – – –
Negative PV 99.4% (99.2–99.5) 99.7% (99.6–99.8) – – – –
Accuracy 83.7% (82.9–84.5) 91.8% (91.0–92.6) – – – –
LR, likelihood ratio; PV, predictive value.
Primary outcomes of pre-eclampsia rates were compared by interrupted time series (ITS) analysis. Comparisons between secondary outcome
groups were by Chi-square or Fisher exact test for categorical variables or Mann–Whitney U-test for continuous variables.
P-values for signficant findings shown in bold.
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versus 3.6%, OR 0.774, 95% CI 0.628–0.953). Although not
reaching statistical significance, there was a trend evident with
reductions of 38, 34 and 19% in early, preterm and term pre-
eclampsia, respectively—and no cases of pre-eclampsia before
30 weeks’ gestation in the FMF screened cohort (Table 2, Fig-
ure 1). When analysed using ITS method, after confirming
rates of pre-eclampsia at various gestations of delivery that
were stable in the NICE (pre-intervention) period, there were
now significant reductions in both the preterm (<37 weeks)
and early pre-eclampsia (<34 weeks) rates at 21 months post
implementation, with relative effective reductions of 80%
(P = 0.025) and 89% (P = 0.017), respectively (Tables 2 and
S4, Figures 2, S3–S5). ITS analysis for pre-eclampsia delivering
at <30 weeks revealed invalid results due to the lack of cases
that inherently affect the analysis. There was a 45% overall
reduction in women with pre-eclampsia needing more than
Figure 1. Graph showing the proportion of women developing pre-eclampsia in weekly gestational epochs in the NICE- and FMF-screened cohorts
(NICE cohort—black bars and dashed line, FMF cohort—grey bars and dotted line).
Figure 2. Graph showing the change in percentage of births complicated by preterm (<37 weeks) pre-eclampsia in quarter-year epochs before (NICE
screened) and after implementation of the FMF screening programme with reference to the general elements of an interrupted time series (ITS)
analysis (pre-slope—dashed lines; change in level—dotted lines; post-slope—solid lines). Dark grey—births with exclusive NICE screening; white—
births containing both NICE and FMF screening; light grey—births with exclusive FMF screening; 10-week lag—pre-viability period (14–24 weeks’
gestation) of the first FMF-screened pregnancies.
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one antihypertensive drug to control blood pressure in the
FMF cohort (Table S5) (15.4 versus 24.8%, OR 0.553, 95% CI
0.323–0.948). This reduction was most evident in the term
pre-eclampsia group, with a three-fold decrease in hyperten-
sion needing treatment with more than one antihypertensive
(16.9 versus 6.4%, P = 0.015). The rates of abnormal haema-
tology, biochemistry, urine PCR, magnesium sulphate use,
HELLP syndrome and eclampsia were not significantly differ-
ent between the cohorts. There were also no significant differ-
ences in the prevalence of small-for-gestational-age birth, fetal
growth restriction, admission to the neonatal intensive care
unit or perinatal mortality (Table S5).
Discussion
Main findings
This study demonstrates the clinical effectiveness of multi-
modal first trimester pre-eclampsia screening and contingent
aspirin prophylaxis. We have shown that this screening pro-
gramme can be implemented in a state-funded, national
healthcare setting and confers a significant improvement in
clinical outcomes compared with current routine practice by
effectively decreasing the screen-positive rate, improving the
targeted use of aspirin prophylaxis and reducing the preva-
lence of preterm pre-eclampsia—all achieved without wors-
ening of pre-eclampsia clinical severity (Video S1).
Strengths and limitations of the study
This study evaluates the effectiveness of an FMF pre-eclampsia
screening programme in a large population of women receiving
routine care in a public health setting. The comparisons of
demographic and medical characteristics, as well as compre-
hensive outcome analysis are among the strengths of this study.
Although we externally validated the ASPRE trial findings, by
implication, a retrospective analysis limits the internal validity
of our study findings. As such, we cannot rule out the possibil-
ity that other concurrent changes in clinical practice, health
environment or population may have contributed to the study
findings. However, by performing the ITS analysis, we have
accounted for the effects of temporal confounders on our pri-
mary outcomes. We acknowledge that the improved targeting
of aspirin and its effect on reducing pre-eclampsia prevalence
would have led to an underestimation of the screening effi-
ciency of the FMF algorithm because of treatment paradox, but
avoiding this effect by withholding aspirin prophylaxis from
such high-risk women would have been unethical.
Interpretation
Clinical implications of study findings
Randomised controlled trials are considered to be the gold
standard in evaluating the effects of treatment, and in this
regard the ASPRE RCT established the efficacy of multi-
modal first trimester pre-eclampsia screening with contin-
gent aspirin prophylaxis in managing pre-eclampsia. To be
clinically meaningful, the external validity (or generalisabil-
ity) of the ASPRE study findings must be established to
determine whether it can overcome the limitations of ‘real
world’ practical implementation, such as differing patient
characteristics, doctor preferences, patient compliance, co-
morbidities and other concomitant interventions. Effective-
ness studies measure the degree of beneficial effect of an
intervention in a pragmatic clinical setting. The introduction
of FMF combined screening improved detection of both pre-
term and term pre-eclampsia despite a two-fold reduction in
the proportion of women identified as at high risk of
pre-eclampsia. The former findings contributed to effective
de-escalation of risk and also led to improved physician
compliance, with 99% of women being prescribed aspirin—a
six-fold improvement on the cohort with NICE screening.
The latter findings of more accurate screening and improved
physician compliance are consistent with a recent study
undertaken to validate the FMF screening algorithm.4
On conventional OR analysis, the FMF screening pro-
gramme resulted in a significant overall 23% reduction in
the prevalence of pre-eclampsia—similar to the 27% reduc-
tion reported in the ASPRE trial.6 The reduction in pre-
eclampsia rates was most evident at preterm gestations, with
no cases being reported before 30 weeks and a 38% reduc-
tion in early pre-eclampsia requiring scheduled birth before
34 weeks’ gestation. The ITS analysis performed to reduce
the influence of temporal confounding factors revealed sig-
nificant reductions in both preterm and early pre-eclampsia
after introduction of the FMF screening programme, with a
21-months relative effect reduction of 80 and 89%, respec-
tively. Conversely, the term pre-eclampsia rate reduction
was not significant by ITS analysis and therefore is most
likely due to confounding factors rather than the FMF
screening programme. This was not unexpected, as the
ASPRE trial did not demonstrate reduction in term pre-
eclampsia and because there was an overall trend to increas-
ing induction of labour in our cohort (Table S1). A recent
RCT, where elective birth at 39 weeks’ gestation resulted in
a 35% lower chance of developing hypertensive disorders of
pregnancy compared with expectant management, provides
evidence for this effect.12 In addition to reducing the preva-
lence of pre-eclampsia, the severity of the disease appeared
not to worsen, with all maternal markers of maternal and
fetal complications (such as pre-eclampsia markers and
poor fetal growth) appearing unchanged in the FMF cohort.
Our findings are consistent not only with a reduction in
pre-eclampsia prevalence but also with a ‘right shift’ in the
clinical presentation of pre-eclampsia to a later gestational
age (Figure 1)—a finding in keeping with a secondary anal-
ysis of the ASPRE efficacy trial.13
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Public health implications of study findings
This study demonstrates that a first trimester combined pre-
eclampsia screening programme is feasible, pragmatic and
effective in a public healthcare setting. Implementation of
this screening programme resulted in de-escalation of risk
for many women with half as many being labelled as high
risk. The manageable screen-positive rate of 8% is likely to
have contributed to the six-fold improvement in physician
compliance, such that 99% of high-risk women were pre-
scribed aspirin prophylaxis at 150 mg. It is important to note
that the dosage of aspirin used in this study has not been
universally adopted by international societies. Aside from the
findings of the ASPRE RCT, the optimal timing and dosage
of aspirin prophylaxis were recently reviewed with the obser-
vation that there was a dose-response effect resulting in
150 mg aspirin conferring the most beneficial effect in pre-
venting pre-eclampsia.14 This finding is readily explained by
several studies demonstrating a 30–40% rate of aspirin resis-
tance in pregnancy that is not evident in the non-pregnant
state.15–17 The near total initiation of effective aspirin pro-
phylaxis as a result of an individualised risk and a universal
‘one-stop’ screening approach is important given the previ-
ously poor rates. This is echoed in the most recent
MBRRACE report, where a number of women at increased
risk were never offered aspirin prophylaxis.18
The findings of this study raise important issues regarding
the process and mechanism of policy-making for the screen-
ing of pre-eclampsia. Screening committees typically com-
mission reviews of evidence for pre-eclampsia as a specific
disorder without giving credence to the fact that pre-eclamp-
sia is defined by signs elicited in pregnancy, where the true
disease is underlying uteroplacental insufficiency with many
other potential manifestations.19 Another example of how
screening may be impacted is the influence of birth, which
introduces significant treatment paradox—birth today pre-
cludes the development of pre-eclampsia tomorrow, even
though the woman may have been destined to develop it.
Hence, conventional sensitivity/specificity and likelihood
ratio analyses used for non-pregnancy conditions such as
cervical cancer are invalid and should be replaced by a com-
peting risk approach analyses.20 Similarly, the use of arbitrary
thresholds to determine whether a screening test may be use-
ful (i.e. likelihood ratio of 10) should be replaced, as they
have only been bench-marked and standardised for routine
screening for conditions outside pregnancy that are well-de-
fined and free of treatment paradox.
Conclusions
First trimester multimodal screening for pre-eclampsia with
aspirin prophylaxis is feasible and effective in a public
health setting. Such an approach results in a two-fold de-
escalation of risk, doubling of pre-eclampsia detection,
almost total physician compliance with aspirin use and
reduction the prevalence of preterm and early pre-eclamp-
sia without any worsening of pre-eclampsia clinical severity.
Given the demonstration of efficacy of such a screening
programme in an RCT and now a demonstration of its
effectiveness in a public healthcare setting, the continued
use of a risk factor-based screening must be re-evaluated.
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Figure S1. Study participant flow chart.
Figure S2. The receiver operator characteristic of an
FMF risk ≥1:50 for the detection of preterm pre-eclampsia
demonstrates excellent discrimination (AUC = 0.846,
P < 0.001).
Figure S3. Colour version of Figure 2. Graph showing
the percentage of births complicated by preterm (<37
weeks) pre-eclampsia in quarter-year epochs before (NICE
screened) and after implementation of the FMF screening
programme with reference to the general elements of an
interrupted time series (ITS) analysis (pre-slope—dashed
lines; change in level—dotted lines; post-slope—solid
lines).
Figure S4. Graph showing the percentage of births com-
plicated by early (<34 weeks) pre-eclampsia in quarter-year
epochs before (NICE screened) and after implementation
of the FMF screening programme with reference to the
general elements of an interrupted time series (ITS) analy-
sis (pre-slope—dashed lines; change in level—dotted lines;
post-slope—solid lines).
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Figure S5. Colour version of Figure S4. Graph showing
the percentage of births complicated by early (<34 weeks)
pre-eclampsia in quarter-year epochs before (NICE
screened) and after implementation of the FMF screening
programme with reference to the general elements of an
interrupted time series (ITS) analysis (pre-slope—dashed
lines; change in level—dotted lines; post-slope—solid lines).
Table S1. Maternal, fetal and neonatal outcomes of the
study population managed with NICE or first trimester
FMF algorithm-based pre-eclampsia screening.
Table S2. Screening performance for preterm pre-
eclampsia delivering before 37 weeks’ gestation for the
NICE-screened (n = 65, 0.84%) and FMF-screened
(n = 27, 0.56%) cohort at various risk cut-offs for pre-
eclampsia <37 weeks.
Table S3. Screening performance for term pre-eclampsia
delivering at or after 37 weeks’ gestation for the NICE-
screened (n = 213, 2.7%) and FMF-screened (n = 109, 2.3%)
cohort at various risk cut-offs for pre-eclampsia <37 weeks.
Table S4. Interrupted time series analysis (ITS) of the %
of births complicated by pre-eclampsia at birth at various
gestational age at delivery using ARIMA modelling.
Table S5. Maternal, fetal and neonatal outcomes of the
pre-eclamptic women managed with NICE or first trimester
FMF algorithm-based pre-eclampsia screening.
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